Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 24 shares of the stock in a transaction dated Friday, November 22nd. The stock was acquired at an average cost of GBX 3,822 ($48.12) per share, for a total transaction of £917.28 ($1,154.83).
Bruce Hiscock also recently made the following trade(s):
Shares of LON BVXP traded up GBX 84 ($1.06) during mid-day trading on Friday, hitting GBX 3,794 ($47.77). The company had a trading volume of 5,647 shares, compared to its average volume of 5,884. The stock's 50-day moving average price is GBX 3,770.97 and its 200-day moving average price is GBX 4,107.58. The company has a market capitalization of £198.05 million, a price-to-earnings ratio of 2,298.16 and a beta of 0.35. Bioventix PLC has a 1 year low of GBX 2,977 ($37.48) and a 1 year high of GBX 5,100 ($64.21).
The company also recently announced a dividend, which was paid on Thursday, November 21st. Investors of record on Thursday, November 7th were issued a dividend of GBX 87 ($1.10) per share. This represents a yield of 2.4%. The ex-dividend date was Thursday, November 7th. This is a positive change from Bioventix's previous dividend of $68.00. Bioventix's dividend payout ratio is 9,693.25%.
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.